Apogee licenses exclusive worldwide rights to IL-31R antibodies from Paragon with up to $23.25M in milestones

Apogee Therapeutics, Inc.

Exclusive worldwide license from Paragon for monospecific antibodies directed to interleukin-31 receptor (IL-31R).
Milestone payments up to $23.25 million, including $5.25 million upon first Phase I dosing.
Low-single digit royalties on net sales of products under the license.
Paragon retains non-exclusive rights for multispecific antibodies; Apogee has right of first negotiation.
Optional CMC activities fees range from $1.3 million to $2.0 million under the discovery agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apogee Therapeutics, Inc. entered into IL-31R Discovery Agreement with Paragon Therapeutics, Inc. (effective 2026-06-17).

Action: entry
Agreement: collaboration
Counterparty: Paragon Therapeutics, Inc.
Effective: 2026-06-17

Exact text from the filing

On June 17, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an antibody discovery agreement with Paragon Therapeutics, Inc. (“Paragon,” and the antibody discovery agreement between the Company and Paragon, the “IL-31R Discovery Agreement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apogee Therapeutics, Inc. entered into IL-31R License Agreement with Paragon Therapeutics, Inc. valued at up to $23.25 million (effective 2026-06-17).

Action: entry
Agreement: license
Counterparty: Paragon Therapeutics, Inc.
Value: up to $23.25 million
Effective: 2026-06-17

Exact text from the filing

On June 17, 2026, contemporaneously with the execution of the IL-31R Discovery Agreement, the Company entered into a license agreement with Paragon (the “IL-31R License Agreement”).

View on SEC.gov

627 material agreements filed in the last 30 days. Browse all material agreements →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-025841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.